• Fight continues to keep moxifloxacin on the 503B bulk drug list

    1 month ago - By Healio

    WAILEA, Hawaii - During the Hawaiian Eye complicated cataract case section here, Richard L. Lindstrom, MD, updated the audience on the fight to retain moxifloxacin as Category 1 for 503B outsourcing facility use.
    Healio previously reported on this in September 2020.
    “I was just on the phone with the FDA on that exact topic a week ago trying to convince them to simply make moxifloxacin still available for 503B compounding, because they want to take it away, which would not be in our best interest,” Richard L. Lindstrom, MD, said here at Hawaiian Eye.
    “AAO, ASCRS, the
    Read more ...